Last reviewed · How we verify
Ferrous bis-glycinate
Ferrous bis-glycinate, marketed by Assiut University, is an iron supplement with a key composition patent expiring in 2028. The drug's key strength lies in its well-established market presence and potentially favorable side effect profile. The primary risk is the patent expiry in 2028, which could lead to increased competition from generic versions.
At a glance
| Generic name | Ferrous bis-glycinate |
|---|---|
| Sponsor | Assiut University |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Potential Harms of Untargeted Iron Supplementation in Cambodia Where Iron Deficiency is Not the Cause of Anemia (PHASE4)
- Iron Sucrose Versus Ferrous Bis-glycinate for Treatment of Iron Deficiency Anemia (PHASE3)
- The Effect of Iron Deficiency Anemia During Pregnancy (PHASE4)
- A Study to Compare the Gastrointestinal Tolerability of Ferrochel®, Sumalate®,Ferrous Fumarate, Ferrous Sulfate, Ferric Glycinate, and Placebo (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ferrous bis-glycinate CI brief — competitive landscape report
- Ferrous bis-glycinate updates RSS · CI watch RSS
- Assiut University portfolio CI